In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211

Autor: Chiara Timperanza, Holger Jensen, Ellinor Hansson, Tom Bäck, Sture Lindegren, Emma Aneheim

Publikováno v: EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-13 (2024)

Abstract Background A significant challenge in cancer therapy lies in eradicating hidden disseminated tumor cells. Within Nuclear Medicine, Targeted Alpha Therapy is a promising approach for cancer treatment tackling disseminated cancer. As tumor siz

Externí odkaz: https://doaj.org/article/278aba369eb9421986b55d1c8c570cee

Astatine-211 based radionuclide therapy: Current clinical trial landscape

Autor: Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, Knut Smerud, Stig Palm

Publikováno v: Frontiers in Medicine, Vol 9 (2023)

Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of

Externí odkaz: https://doaj.org/article/d22308bdcbb6401cb0e87576be06c2cb

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211

Autor: Chiara Timperanza, Holger Jensen, Tom Bäck, Sture Lindegren, Emma Aneheim

Publikováno v: Pharmaceuticals, Vol 16, Iss 4, p 595 (2023)

To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumor is pretargeted with a modified monoclonal antibody that has an affinity

Externí odkaz: https://doaj.org/article/59623e6c974e4e15996073c8c88b1448

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model

Autor: Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, Ragnar Hultborn, Stig Palm, Lars Jacobsson, Alfred Morgenstern, Frank Bruchertseifer, Per Albertsson, Sture Lindegren

Publikováno v: EJNMMI Research, Vol 7, Iss 1, Pp 1-8 (2017)

Abstract Background The aim of this study was to compare the therapeutic efficacy of two different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. Sixty female BALB/c (nu/nu) mice were inoculated intraperiton

Externí odkaz: https://doaj.org/article/9db342e805264a548da9e9feb6f45337

Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy

Autor: Holger Jensen, Matthias M. Herth, Emma Aneheim, Andreas Kjaer, Paul J. Kempen, Andreas Tue Ingemann Jensen, Emanuel Sporer, Tom Bäck, Sture Lindegren, Christian B. M. Poulie

Publikováno v: Sporer, E, Poulie, C B M, Lindegren, S, Aneheim, E, Jensen, H, Bäck, T, Kempen, P J, Kjaer, A, Herth, M M & Jensen, A I 2021, ' Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy ', Journal of Nanotheranostics, vol. 2, no. 4, pp. 196-207 . https://doi.org/10.3390/jnt2040012
Journal of Nanotheranostics, Vol 2, Iss 12, Pp 196-207 (2021)
Capital Region of Denmark

Targeted α-therapy (TAT) can eradicate tumor metastases while limiting overall toxicity. One of the most promising α-particle emitters is astatine-211 (211At). However, 211At-carbon bonds are notoriously unstable in vivo and no chelators are availa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6af0f49e9d15019e6a3be033660fa7f
https://doi.org/10.3390/jnt2040012